Contenido principal del artículo

Pilar Tamayo-Alonso
Hospital Universitario de Salamanca. Servicio de Medicina Nuclear. Salamanca. España
España
https://orcid.org/0000-0002-7466-514X
Esther Martín-Gómez
Hospital Universitario de Salamanca. Servicio de Medicina Nuclear. Salamanca. España
España
https://orcid.org/0000-0001-6019-5928
Paloma García-Talavera
Hospital Universitario de Salamanca. Servicio de Medicina Nuclear. Salamanca. España
España
José Cañadas-Salazar
Hospital Universitario de Salamanca. Servicio de Medicina Nuclear. Salamanca. España
España
https://orcid.org/0000-0002-4182-9566
Carolina Peñaherrera-Cepeda
Hospital Universitario de Salamanca. Servicio de Medicina Nuclear. Salamanca. España
España
https://orcid.org/0000-0003-3789-715X
Luis Gonzaga Díaz-González
Hospital Universitario de Salamanca. Servicio de Medicina Nuclear. Salamanca. España
España
Vol. 12 Núm. 4 (2021), Artículo de revisión, Páginas 371-380
DOI: https://doi.org/10.14201/orl.25746
Derechos de autor Cómo citar

Resumen

El tratamiento del carcinoma diferenciado de tiroides (CDT) con radioyodo (RAI) se viene realizando durante más de 70 años. Sin embargo, no existe consenso en cuanto a indicaciones, dosis y otros aspectos relacionados con el cuidado de los pacientes. Es más, en los últimos años se ha cuestionado la necesidad de terapia adicional con RAI en los pacientes con carcinoma diferenciado de tiroides (CDT) tras la cirugía, como lo ha hecho la guía ATA 2015. Cuestionamiento que no ha sido suscrito por las sociedades Europea y Americana de Medicina Nuclear (EANM y SNMIM, respectivamente), lo que ha dado lugar a se produzcan encuentros (Encuentros de La Martinica) entre la EANM, la SNMIM y las Sociedades Americana (ATA) y Europea de Tiroides (ETA). Se han celebrado dos encuentros, en 2018 y 2019, en los que se establecieron unos principios (Principios de La Martinica). Estos principios y los resultados de las publicaciones más recientes, en cuanto a la potencialidad de la terapia con RAI en pacientes con CDT, van a ser objeto de desarrollo en este trabajo para llevar a cabo una actualización del tratamiento del CDT con RAI.

Descargas

La descarga de datos todavía no está disponible.

Detalles del artículo

Citas

Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012 Dec;33(6):920–80.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1–133.

Verburg FA, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, et al. Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Vol. 43, European Journal of Nuclear Medicine and Molecular Imaging. Springer Berlin; 2016, pp. 1001–5.

Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2008 Jun;37(2):457–80.

Van Nostrand D. Selected Controversies of Radioiodine Imaging and Therapy in Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am. 2017 Sep;46(3):783–93.

National_Cancer_Institute. NCI dictionary of cancer terms. No Title [Internet]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adjuvant-therapy

Tuttle RM, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Daniels GH, et al. Controversies, Consensus, and Collaboration in the Use of (131)I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. Thyroid. 2019 Apr;29(4):461–70.

Yang SP, Bach AM, Tuttle RM, Fish SA. Serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in low-risk papillary thyroid cancer patients. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2015 Dec;21(12):1372–9.

Lee S-W. SPECT/CT in the Treatment of Differentiated Thyroid Cancer. Nucl Med Mol Imaging (2010). 2017 Dec;51(4):297–303.

Avram AM, Esfandiari NH, Wong KK. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. J Clin Endocrinol Metab. 2015 May;100(5):1895–902.

Al-Qahtani KH, Al Asiri M, Tunio MA, Aljohani NJ, Bayoumi Y, Fatani H, et al. Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected]. J Otolaryngol Head Neck Surg. 2015 Dec;44:51.

Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: A systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010 Nov;20(11):1235–45.

Lamartina L, Durante C, Filetti S, Cooper DS. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: A systematic review of the literature. J Clin Endocrinol Metab. 2015;100(5):1748–61. Disponible en: https://academic.oup.com/jcem/article/100/5/1748/2829609

Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004 Aug;89(8):3668–76.

Groopman J, Hartzband P. Your medical mind. How to decide what is right for you. Penguin Books, New York; 2011.

Differentiated thyroid cancer: Is there a need for radioiodine ablation in low risk patients? (ESTIMABL2). ClinicalTrials.gov website, [Internet]. Published April 23. 2013 [cited 2018 Jul 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01398085

IoN: Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients (IoN). ClinicalTrials.gov website. [Internet]. July 20,2011. [cited 2018 Jul 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01398085

Luster M, Aktolun C, Amendoeira I, Barczy?ski M, Bible KC, Duntas LH, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019 Jan;29(1):7–26.

Verburg FA, Flux G, Giovanella L, van Nostrand D, Muylle K, Luster M. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):78–83.

Grewal RK, Larson SM, Pentlow CE, Pentlow KS, Gonen M, Qualey R, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med. 2009 Oct;50(10):1605–10.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012 May;366(18):1674–85.

Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012 May;366(18):1663–73.

Schlumberger M, Leboulleux S, Catargi B, Deandreis D, Zerdoud S, Bardet S, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): lancet Diabetes Endocrinol. 2018 Aug;6(8):618–26.

Dehbi H-M, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019 Jan;7(1):44–51.

Estorch M, Mitjavila M, Muros MA, Caballero E. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature. Rev Esp Med Nucl Imagen Mol. 2019 Jun;38(3):195–203.

Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid. 2005 Dec;15(12):1321–31.

Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid. 2000 Jul;10(7):573–7.

Lee JW, Lee SM, Koh GP, Lee DH. The comparison of (131) I whole-body scans on the third and tenth day after (131)I therapy in patients with well-differentiated thyroid cancer: preliminary report. Ann Nucl Med. 2011 Jul;25(6):439–46.

Verburg FA, Ahuja S, Avram AM, Bardiès M, Bernet V, Bourguet P, et al. Brief progress report from the intersocietal working group on differentiated thyroid cancer. Vol. 47, European journal of nuclear medicine and molecular imaging. 2020, pp. 1345–7.

Artículos más leídos del mismo autor/a